Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment Selection for Patients with HER2-Negative Metastatic Gastric Cancer Expressing Claudin 18.2 and PD-L1

27 Mar 2025

Abstract excerpt

Combination therapy of chemotherapy and zolbetuximab demonstrated a significant survival benefit compared to chemotherapy alone in patients with human epidermal growth factor receptor 2 (HER2)-negative, claudin (CLDN) 18.2-positive metastatic gastric cancer (mGC). Consequently, it has been approved as a standard first-line therapy for these patients. Combination therapy of chemotherapy and immune checkpoint...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Immunotherapy and Biomarkers
Share to Gastric Cancer Management and Outcomes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40227631
DOI: 10.3390/cancers17071120

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment Selection for Patients with HER2-Negative Metastatic Gastric Cancer Expressing Claudin 18.2 and PD-L1PMID 40227631Read ↗

Prognostic significance of Claudin18.2 expression in patients with gastric cancer: Insights from original research and meta-analysisSemantic proximity Read ↗

Artificial intelligence-based prediction of claudin 18.2 expression and immune phenotype from routine histology to guide treatment decisions in patients with gastric cancer.Semantic proximity Read ↗

Antibody-Mediated Therapy in Gastric Cancer: Past, Present, and FutureSemantic proximity Read ↗

Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody DevelopmentSemantic proximity Read ↗

Advanced gastric cancer: Current treatment landscape and future perspectives.Semantic proximity Read ↗

Concordance of claudin-18.2 expression in biopsy, resection, and recurrent specimens: implications for zolbetuximab therapy in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Spatial expression of claudin 18.2 in matched primaries and metastases of tubo-ovarian carcinoma of all subtypesSemantic proximity Read ↗

Exploring the therapeutic efficacy difference in claudin18.2-targeted cell therapy revealed by single-cell sequencingSemantic proximity Read ↗

Genetic Predictors of Response to Zolbetuximab in Gastric AdenocarcinomaSemantic proximity Read ↗

Car-γδ T Cells Targeting Claudin18.2 Show Superior Cytotoxicity Against Solid Tumor Compared to Traditional Car-αβ T CellsSemantic proximity Read ↗

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Claudin 18 (43–14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.